LNTH
NEUTRAL
$80.59
Live
Lantheus Holdings, Inc. · NASDAQ
Target $91.38
(+13.4%)
$47.25
52W Range
$108.91
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$5.25B
P/E
23.63
ROE
21.4%
Profit margin
15.2%
Debt/Equity
0.57
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LNTH exhibits strong operational health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.70), though it lacks an Altman Z-Score for bankruptcy benchmarking. While the company is highly profitable with an ROE of 21.45% and a consistent track record of earnings beats, the stock trades at a significant premium to its Graham Number ($35.98) and Intrinsic Value ($23.87). The bullish outlook is supported by a low Forward P/E of 12.81 and a positive analyst target of $91.38, but the current price is disconnected from deterministic value metrics.
Key Strengths
Strong financial health indicated by a Piotroski F-Score of 7/9
Excellent liquidity with a Current Ratio of 2.70 and Quick Ratio of 2.20
High profitability with 21.45% ROE and 61.10% Gross Margin
Consistent history of earnings surprises, beating estimates in 3 of the last 4 quarters
Low leverage compared to sector averages (Debt/Equity 0.57 vs Sector 3.75)
Key Risks
Significant valuation gap between current price ($80.59) and Graham Number ($35.98)
Modest year-over-year revenue growth of only 4.00%
Bearish technical trend (0/100) despite recent 6-month recovery
Lack of dividend yield provides no floor for long-term income investors
High Price/Book ratio (4.78) suggests expensive entry relative to assets
AI Fair Value Estimate
Based on comprehensive analysis
$62.5
-22.4% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
55
Moderate
30
70
85
90
0
AI Verdict
Operationally strong but fundamentally overvalued
Key drivers: Piotroski F-Score, Forward P/E compression, Graham Number discrepancy
Confidence
80%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (12.81) is attractive
Watchpoints
- Price is >2x the Graham Number
- Price is >3x the Intrinsic Value
Future
70/100
Ref Growth rates
Positives
- Strong earnings beat trajectory
- Positive analyst price target ($91.38)
Watchpoints
- Slow top-line revenue growth (4%)
Past
85/100
Ref Historical trends
Positives
- 5-year price change of +283.6%
- Consistent quarterly EPS growth
Watchpoints
- 1-year return is negative (-18.2%)
Health
90/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score 7/9
- Low Debt/Equity ratio
- Strong current and quick ratios
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$80.59
Analyst Target
$91.38
Upside/Downside
+13.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LNTH and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
Primary
|
+283.6% | -6.7% | -18.2% | +50.5% | -2.5% | +5.9% |
|
CAI
Caris Life Sciences, Inc.
Peer
|
-33.0% | -33.0% | -33.0% | -40.6% | -1.3% | +4.9% |
|
ALKS
Alkermes plc
Peer
|
+40.1% | +3.5% | -17.4% | +2.9% | -20.5% | -3.0% |
|
FOLD
Amicus Therapeutics, Inc.
Peer
|
+55.8% | +30.6% | +110.0% | +75.0% | +0.8% | +0.2% |
|
BLCO
Bausch + Lomb Corporation
Peer
|
-15.1% | -0.2% | +0.8% | +18.6% | -0.2% | -1.1% |
LNT
Lantheus Holdings, Inc.
Primary
5Y
+283.6%
3Y
-6.7%
1Y
-18.2%
6M
+50.5%
1M
-2.5%
1W
+5.9%
CAI
Caris Life Sciences, Inc.
Peer
5Y
-33.0%
3Y
-33.0%
1Y
-33.0%
6M
-40.6%
1M
-1.3%
1W
+4.9%
ALK
Alkermes plc
Peer
5Y
+40.1%
3Y
+3.5%
1Y
-17.4%
6M
+2.9%
1M
-20.5%
1W
-3.0%
FOL
Amicus Therapeutics, Inc.
Peer
5Y
+55.8%
3Y
+30.6%
1Y
+110.0%
6M
+75.0%
1M
+0.8%
1W
+0.2%
BLC
Bausch + Lomb Corporation
Peer
5Y
-15.1%
3Y
-0.2%
1Y
+0.8%
6M
+18.6%
1M
-0.2%
1W
-1.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
23.63
Forward P/E
12.81
PEG Ratio
N/A
P/B Ratio
4.78
P/S Ratio
3.4
EV/Revenue
3.55
EV/EBITDA
14.31
Market Cap
$5.25B
Profitability
Profit margins and return metrics
Profit Margin
15.15%
Operating Margin
19.07%
Gross Margin
61.1%
ROE
21.45%
ROA
9.28%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+4.01%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.57
Moderate
Current Ratio
2.7
Strong
Quick Ratio
2.2
Excellent
Cash/Share
$5.56
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
59.2%
Op. Margin
19.0%
Net Margin
13.3%
Total Assets
$2.2B
Liabilities
$1.1B
Equity
$1.1B
Debt/Equity
1.04x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
90%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-26
$1.67
+42.9% surprise
2025-11-06
$1.27
+0.2% surprise
2025-08-06
$1.12
+623.4% surprise
Healthcare Sector Comparison
Comparing LNTH against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
23.63
This Stock
vs
87.11
Sector Avg
-72.9%
(Discount)
Return on Equity (ROE)
21.45%
This Stock
vs
-49.88%
Sector Avg
-143.0%
(Below Avg)
Profit Margin
15.15%
This Stock
vs
-9.43%
Sector Avg
-260.6%
(Weaker)
Debt to Equity
0.57
This Stock
vs
3.74
Sector Avg
-84.7%
(Less Debt)
Revenue Growth
4.0%
This Stock
vs
80.78%
Sector Avg
-95.0%
(Slower)
Current Ratio
2.7
This Stock
vs
3.72
Sector Avg
-27.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
NEUTRAL | $5.25B | 23.63 | 21.4% | 15.2% | $80.59 | |
|
CAI
Caris Life Sciences, Inc.
|
NEUTRAL | $5.3B | - | -45.4% | -8.4% | $18.75 | Compare |
|
ALKS
Alkermes plc
|
BEARISH | $4.63B | 19.41 | 14.7% | 16.4% | $27.76 | Compare |
|
FOLD
Amicus Therapeutics, Inc.
|
BEARISH | $4.54B | - | -11.6% | -4.3% | $14.47 | Compare |
|
BLCO
Bausch + Lomb Corporation
|
BEARISH | $6.01B | - | -4.5% | -6.1% | $16.98 | Compare |
LNTH
Lantheus Holdings, Inc.
NEUTRAL
Mkt Cap
$5.2B
P/E
23.6
ROE
21.4%
Price
$80.59
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | NIEDZWIECKI DANIEL M. | General Counsel | Stock Award | 36,692 | - |
| 2026-03-05 | MORGAN AMANDA MICHELLE | Officer | Stock Award | 26,208 | - |
| 2026-03-05 | BROWN KIMBERLY | Officer | Stock Award | 6,158 | - |
| 2026-03-05 | DINKELBORG LUDGER | Officer | Stock Award | 20,966 | - |
| 2026-03-05 | MARSHALL ROBERT J. JR. | Chief Financial Officer | Stock Award | 38,002 | - |
| 2026-03-02 | NIEDZWIECKI DANIEL M. | General Counsel | Stock Award | 5,169 | - |
| 2026-03-02 | MORGAN AMANDA MICHELLE | Officer | Stock Award | 2,782 | - |
| 2026-03-02 | HEINO MARY ANNE | Chief Executive Officer | Stock Award | 32,105 | - |
| 2026-03-02 | MARSHALL ROBERT J. JR. | Chief Financial Officer | Stock Award | 8,491 | - |
| 2025-11-17 | HEINO MARY ANNE | Officer and Director | Stock Award | 14,285 | - |
NIEDZWIECKI DANIEL M.
General Counsel
2026-03-05
36,692 shares
MORGAN AMANDA MICHELLE
Officer
2026-03-05
26,208 shares
BROWN KIMBERLY
Officer
2026-03-05
6,158 shares
DINKELBORG LUDGER
Officer
2026-03-05
20,966 shares
MARSHALL ROBERT J. JR.
Chief Financial Officer
2026-03-05
38,002 shares
NIEDZWIECKI DANIEL M.
General Counsel
2026-03-02
5,169 shares
MORGAN AMANDA MICHELLE
Officer
2026-03-02
2,782 shares
HEINO MARY ANNE
Chief Executive Officer
2026-03-02
32,105 shares
MARSHALL ROBERT J. JR.
Chief Financial Officer
2026-03-02
8,491 shares
HEINO MARY ANNE
Officer and Director
2025-11-17
14,285 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
13 analysts
Truist Securities
2026-03-02
Buy
Buy
Mizuho
2026-02-27
Outperform
Outperform
Citizens
2026-02-27
Market Outperform
Market Outperform
Jones Trading
2026-02-27
Buy
Hold
Citizens
2026-02-24
Market Outperform
Market Outperform
Truist Securities
2025-12-18
Buy
Buy
Mizuho
2025-12-17
Outperform
Outperform
Truist Securities
2025-12-12
Hold
Buy
Truist Securities
2025-11-10
Hold
Hold
Past News Coverage
Recent headlines mentioning LNTH from our newsroom.
Newest → oldest
No matching news yet.